The purpose of the study is to investigate the Metabolite identification and material balance of SP2086 in healthy adult volunteers.
All subjects were given SP2086 100mg only one time, and blood sample should be collected before and 96 hours after medicine taken.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
8
SP2086 was taken only one time at 100mg dose in health volunteers
The maximum plasma concentration (Cmax) of SP2086
Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of multiple doses of SP2086
Time frame: up to 96 hours
The maximum plasma concentration (Cmax) of SP2086 acid
Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086
Time frame: up to 96 hours
The area under the plasma concentration-time curve (AUC) of SP2086
AUC (a measure of the body's exposure to SP2086) will be compared before and after administration of multiple doses of SP2086
Time frame: up to 96 hours
The area under the plasma concentration-time curve (AUC) of SP2086 acid
AUC (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086
Time frame: up to 96 hours
The number of volunteers with adverse events as a measure of safety and tolerability
Time frame: up to 96 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.